Innovative Diagnostic Technology Braingaze specializes in translating eye movement analysis into actionable markers for cognitive disorders such as ADHD and Alzheimer's, offering unique digital health solutions that could be integrated into broader diagnostic or therapeutic workflows.

Strategic Industry Collaborations The company's recent partnership with Tris Pharma and participation in PepsiCo's Greenhouse Accelerator highlight opportunities for partnerships with pharmaceutical, consumer health, and wellness sectors seeking innovative mental health tools.

Expanding Application Portfolio With the launch of ADHD diagnostic software and therapy apps across multiple platforms, there is potential to expand into additional neurobehavioral conditions or develop tailored solutions for specialized clinic networks.

Growing Market Presence Although currently with modest revenue levels, Braingaze's involvement in clinical settings and recent funding milestones position it well to penetrate global healthcare markets focused on cognitive health and digital therapeutics.

Technology & Data Capabilities Leveraging patented eye movement markers and AI expertise, Braingaze can offer scalable, data-driven solutions for healthcare providers and research institutions aiming to enhance cognitive disorder diagnosis and monitoring.